Call for Editor-in-Chief of New Peer-Reviewed Journal, *GEN Biotechnology*

The leading publisher in the biomedical and biotechnology industries, Mary Ann Liebert, Inc., has an exceptional opportunity for an academic or industry scientist to play a pivotal role in driving the launch and growth of a major new hybrid peer-reviewed journal in 2022, *GEN Biotechnology*.

We are seeking a dynamic, innovative, and passionate Editor-in-Chief (EIC) to take the helm of the journal, working with an experienced professional editorial team and a talented editorial advisory board.

Publishing in print and online, *GEN Biotechnology* will bring together the dynamic, global media presence of *Genetic Engineering & Biotechnology News* (GEN) with the scientific peer-reviewed publishing expertise of Mary Ann Liebert, Inc. We offer best-in-class author services, rapid and constructive peer review, and international exposure across the leading media platforms in the industry.

*GEN Biotechnology* will sit alongside other preeminent biomedical journals in the Mary Ann Liebert, Inc. portfolio, including *Human Gene Therapy*, *The CRISPR Journal*, and *Tissue Engineering*. It will publish advances across all aspects of basic and translational biotechnology research, including drug discovery, cell and gene therapy, immunotherapy, genome editing, genomics, artificial intelligence, bioengineering, agricultural biotechnology, AI, environmental biotechnology, neuroscience, cancer research, diagnostics, and more.

The Journal will place a premium on original research articles, comprehensive review articles, but will also publish a selection of news and analysis stories, interviews, and commentaries, with contributions from the GEN editorial team.

The EIC role will begin in September/October 2021 with a multi-year appointment. We anticipate the EIC spending about 5 hours per week devoted to journal affairs. The journal will begin publishing in Spring 2022.

Applications for and inquiries about the EIC position can be emailed to Dr. Kevin Davies, Vice President, at kdavies@liebertpub.com. Applicants are required to submit a CV and a statement of interest that includes their vision for the journal (details below).

**Position Expectations:**
The role of the EIC is to provide editorial oversight and strategy, to recruit and attract submissions to the journal, and to ensure the timeliness of publication of all journal content. The EIC will establish the working management of the journal, including appointing editorial board members and establishing a team of dedicated Associate Editors to manage manuscript submissions. The EIC is responsible for communicating with authors and reviewers, as needed, regarding substantive manuscript content and review queries, and will ensure all standards for scientific publishing, including adherence to publication ethics, are adhered to, maintained, and implemented.

**Core Responsibilities:**
The EIC will develop and implement aggressive editorial goals for *GEN Biotechnology*. One of the main priorities of the EIC is to solicit original research and review articles on key topics, be a fundamental advocate for the journal. *GEN Biotechnology* is a hybrid subscription journal that offers authors open access publishing options.

The EIC will oversee the peer-review process, along with appointed Associate Editors. The EIC will work with his/her editorial team, reviewers and authors to ensure each manuscript is worthy of consideration, peer-reviewed in a timely fashion, and, if selected for publication, revised until ready for publication. The
EIC is responsible to adhere to all publisher deadlines, and to work within the ScholarOne Manuscript Central peer review database.

**Requirements:**

- Highly organized, motivated individual with the skills and talent to develop a highly competitive new journal in an aggressive marketplace
- Broad research interests relevant to an area of biotechnology and a record of successful publication
- Editorial and peer review experience in biomedical or biotechnology journals
- Publishing experience as an author; reviewing and/or editorial board member experience highly desirable
- Experience with online manuscript submission systems is a plus; willingness to learn and use ScholarOne Manuscript Central system
- Strong network and reputation nationally and internationally
- Advocacy for open access publishing and social media
- This is an independent-contractor position (with honorarium)

**Application must include:**

- Curriculum Vitae
- Link to professional website
- A letter of interest outlining your plans and aspirations for **GEN Biotechnology** (500 words)

Please send materials via email to Dr. Kevin Davies, Vice President, at kdavies@liebertpub.com